A mixture of three cell types self-assembles into a liver bud that can be seen with the naked eye. In work that will raise hope that organs could be repaired or even grown from scratch using a patient’s own tissue as the raw material, Japanese researchers have created functioning liver tissue from stem cells and successfully transplanted them into mice.
Volcano agreed to give Crux Biomedical an extra 5 months to obtain FDA 510(k) clearance for a retrieval device, a milestone worth $3 million under the terms their merger agreement. Under the amended agreement Crux has until Nov. 30, 2013, to win FDA clearance and satisfy the milestone.
CEA-Leti Announces €1 Million from bpifrance to Speed Preclinical Development of Cancer-Detecting NanoparticlesJuly 3, 2013 12:15 pm | by CEA-Leti | News | Comments
CEA-Leti has announced €1 million in funding from bpifrance to accelerate preclinical development of a liver-cancer detection system called LipImage 815. The grant will accelerate the development of LipImage 815, including production and regulatory toxicity evaluation.
A nonsurgical procedure offered at the University of Florida Health Spine & Sports Intervention Center uses Cervicool, a water-cooled radiofrequency system by Kimberly-Clark Corp., to treat the facet joints in the neck to relieve pain.
Medtronic (NYSE:MDT) prevailed in an antitrust lawsuit filed over a bone mill made by Lenox MacLaren Surgical, with a federal judge ruling that Lenox misrepresented the size of the bone mill market and failed to adequately market its own device.
A research team headed by Dr. Mitsuhiro Ebara, a MANA Scientist of the Biomaterials Unit of the International Center for Materials Nanoarchitectonics, National Institute for Materials Science, developed a new nanofiber mesh which is capable of simultaneously realizing thermotherapy and chemotherapy of tumors.
GI Dynamics said it's raised roughly $52.2 million in a private placement and is offering another $2.3 million in a stock purchase plan for existing shareholders. The Lexington, Mass.-based medical device company said it plans to use the cash to fund a U.S. clinical trial of its EndoBarrier weight loss and diabetes treatment, a plastic sleeve used to line the gut to inhibit the uptake of nutrients from food.
A new automated diagnostic test can quickly and accurately identify most leading causes of Gram-positive bacterial blood stream infections and the presence of three antibiotic resistance genes, according to a new study published this week in PLOS Medicine.
Neurodegenerative diseases such as Alzheimer's could be better understood thanks to insight into proteins linked to such conditions, a study suggests. Scientists studying thread-like chains of protein have found that low levels of these proteins may cause more harm to health than high levels.
The introduction of CT pulmonary angiography has been associated with an 80% rise in the detection of pulmonary emboli in the US, but with little change in death rates. Professor Renda Soylemez Wiener and colleagues argue this is evidence of overdiagnosis.
Older adults diagnosed with brain disorders such as Parkinson’s disease often feel a loss of independence because of their lack of mobility and difficulty walking. To better understand and improve these mobility issues, a research team is working toward building a more advanced motion test.
In new research, Hao Yan and his colleagues at Arizona State University's Biodesign Institute describe a pair of tweezers shrunk down to an astonishingly tiny scale. When the jaws of these tools are in the open position, the distance between the two arms is about 16 nanometers.
Early-stage MitrAssist whizzed by it's hoped-for raise of $600,000, landing $1 million from angel and private investors in support of the company's mitral valve implant. MitrAssist, a spin-out of Tredline Group's accelerator program, is developing what it calls a "valve-on-valve" approach to treat mitral regurgitation for patients too elderly or unstable for an invasive open-heart operation.
New York-based lifesciences investment group Iguana Healthcare Partners filed an amended notice, reporting that the company has raised more than $53.5 million in pooled investment fund interests. The funding, raised among 20 unnamed investors, will support Iguana's interests in pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare services and healthcare information technology.
One of the greatest pleasures I have as FDA commissioner is the opportunity to meet with so many who are making a real difference in the world of health care, including researchers, doctors, drug industry leaders, foundations, and advocates for patients and families, including most recently the Alexandria Summit for Oncology.